Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective, randomized, double-blind, placebo-controlled Phase 3 study of dapoxetine in men with co-existing erectile dysfunction and premature ejaculation
2009-013616-12Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in premature ejaculation (PE) and erectile dysfunction (ED) comparing Dapoxetine arm with Placebo arm (2 arms). Primary endpoint: Average intravaginal ejaculatory latency time at Week 12 (LPOCF). Started Mar 2010; status: completed.
02
Drugs
dapoxetine
03
Conditions
premature ejaculation (PE)erectile dysfunction (ED)
Beyond the preview
Go deeper on 2009-013616-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013616-12.